Results 311 to 320 of about 87,642 (357)

Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma

International Archives of Allergy and Immunology, 2023
Introduction: Mucus plugs are associated with airway obstruction in severe asthma and are involved in the formation of activated eosinophils. Benralizumab, an anti-interleukin-5 receptor antibody, markedly reduces not only peripheral blood eosinophils ...
Natsumi Sakai, T. Koya, Yuihci Murai, F. Tsubokawa, Kentaro Tanaka, S. Naramoto, A. Aoki, K. Shima, Y. Kimura, Satoshi Watanabe, T. Hasegawa, T. Kikuchi   +11 more
semanticscholar   +1 more source

The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma

European Respiratory Journal, 2023
Extract Asthma and obesity are prevalent disorders with significant impact on public health. Obesity is a reported risk factor for the development of asthma and is associated with increased exacerbation rates, medication usage and higher symptoms scores ...
A. Nanzer, Victoria Taylor, A. Hearn, J. Kavanagh, Tanya Patrick, L. Green, L. Thomson, J. Lam, Mariana Fernandez, C. Roxas, G. D'ancona, B. Kent, J. Dhariwal, D. Jackson   +13 more
semanticscholar   +1 more source

Mepolizumab in the Treatment of Severe Eosinophilic Asthma

Immunotherapy, 2015
IL-5 is crucial in the pathogenesis and evolution of eosinophilic asthma. Mepolizumab is a high-affinity humanized monoclonal antibody of the IgG1/k subtype that inhibits the binding of IL-5 to its receptor expressed on eosinophils, thereby inducing significant reduction in eosinophil circulation, as well as asthma exacerbations and corticosteroid ...
FAINARDI, Valentina, PISI, GIOVANNA, CHETTA, Alfredo Antonio   +2 more
openaire   +3 more sources

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Allen L. Wolford, Melissa F. Waineo, Shawna M. Cargill, Mara N. Poulakos   +3 more
openaire   +2 more sources

Eosinophils in the pathogenesis of paediatric severe asthma

Current Opinion in Allergy & Clinical Immunology, 2014
The importance and functional contribution of eosinophils to the pathogenesis of severe asthma was questioned when adult studies reported neutrophilic inflammation and Th17 cells were central to disease.Eosinophilic inflammation, atopic sensitization and airway remodelling are the hallmark features of severe asthma in children.
Clare M. Lloyd, Sejal Saglani
openaire   +3 more sources

RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Allergy. European Journal of Allergy and Clinical Immunology, 2022
R E FE R E N C E S 1. Zuberbier T, Aberer W, Asero R, et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN ...
M. Kallieri, E. Zervas, E. Fouka, Konstantinos Porpodis, Marija Hadji Mitrova, E. Tzortzaki, M. Makris, Maria Ntakoula, A. Papaioannou, P. Lyberopoulos, K. Dimakou, S. Koukidou, S. Ampelioti, A. Papaporfyriou, K. Katsoulis, M. Kipourou, N. Rovina, K. Antoniou, S. Vittorakis, P. Bakakos, P. Steiropoulos, K. Markopoulou, Panteleimon Avarlis, Ιlias C. Papanikolaou, Miltiadis Markatos, Eleni Gaki, K. Samitas, K. Glynos, S. Papiris, D. Papakosta, N. Tzanakis, M. Gaga, K. Kostikas, S. Loukides   +33 more
semanticscholar   +1 more source

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
S. J. Williams, W. H. Taylor, T. J. Charles, A. Seaton, Christine Bruce   +4 more
openaire   +3 more sources

Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

Journal of Asthma, 2022
Introduction Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations.
C. Menigoz, S. Dirou, A. Chambellan, D. Hassoun, A. Moui, A. Magnan, F. Blanc   +6 more
semanticscholar   +1 more source

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +3 more sources

Prognostic factors in severe eosinophilic asthma

Monitoring Airway Disease, 2018
Introduction: Uncontrolled Severe Eosinophilic Asthma (USEA) represents a challenging health problem. Characterize variables that predict poor control in this patients to will improve its management. The aim was identify the factors of poor control of severe eosinophilic asthma. Methodes: Were collected 78 patients of our Asthma Severe Unit.
Filipe Gonçalves Dos Santos Carvalho, Alicia Francoso Vicente, Maria Del Mar Martinez Colls, Marisa Rivera Ortún, Albert Roger, Eva Martinez Cáceres, Carlos Pollan Guisasola, Maria Basagaña Torrento, Carlos Martinez Rivera, Juan Ruiz Manzano, Aina Teniente, Clara Padró Casas   +11 more
openaire   +5 more sources